Avarieux
back to explore
Aclaris Therapeutics Inc logo

ACRS

Aclaris Therapeutics Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2015-10-07
$6.15
-0.03 (-0.49%)
last quote
Want the full multi-source brief on ACRS?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
open in agent
Today
Open
$6.15
High
$6.27
Low
$6.08
Previous close
$6.18
Fundamentals
Market cap
$886.87M
P/E (TTM)
—
P/S (TTM)
107.91x
P/B
3.16x
Gross margin
12.90%
Operating margin
-1050.16%
Net margin
-921.50%
Rev growth (YoY)
-51.05%
EPS growth (YoY)
—
ROE
-61.65%
52W high
$6.60
52W low
$1.74
Beta
0.93x
Industry peers
by market cap
PCRX-0.24%AMPH-1.07%LXRX-0.22%SGP+1.93%COLL-2.14%PHAT-2.05%CRMD-0.75%AQST-2.14%
Upcoming earnings
next 30 days
2026-11-04in 61 days
Q3 2026EPS est $-0.17Rev est $1.3M
Recent SEC filings
CIK 1557746filing-language history →
SCHEDULE 13G/A2026-08-14
14 KB
8-K2026-08-06
462 KB
S-3ASR2026-08-06
1,722 KB
10-Q2026-08-06reports 2026-06-30
6,940 KB
8-K2026-08-06
353 KB
42026-08-04reports 2026-08-01
9 KB
Recent news
2026-08-27 → 2026-09-03
Benzinga · 2d
Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10
Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $10.
SEC EDGAR Yahoo Finance TradingView Company website
This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial